1017553-74-0

Basic information

• Product Name: 2-(pyridin-3-yl)cyclopropanecarboxylic acid
• CAS NO: 1017553-74-0
• Mol File: 1017553-74-0.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-(pyridin-3-yl)cyclopropanecarboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(pyridin-3-yl)cyclopropanecarboxylic acid(1017553-74-0)
• EPA Substance Registry System: 2-(pyridin-3-yl)cyclopropanecarboxylic acid(1017553-74-0)

Safety Data

• Hazardous Substances Data: 1017553-74-0(Hazardous Substances Data)

Usage

General Description

2-(pyridin-3-yl)cyclopropanecarboxylic acid is a chemical compound with the molecular formula C10H9NO2. It is a derivative of cyclopropanecarboxylic acid, with a pyridine ring attached at the 2-position. 2-(pyridin-3-yl)cyclopropanecarboxylic acid is used in organic synthesis and pharmaceutical research as a building block for the synthesis of biologically active molecules. It has been investigated for its potential as a drug candidate for various therapeutic applications, including anti-cancer and anti-inflammatory properties. The presence of the cyclopropane and pyridine moieties in the structure contributes to its unique chemical and biological properties, making it a valuable tool for drug discovery and development.

Upstream product

• 100390-47-4 C₁₂H₁₅NO₂ 
• 1126-74-5 3-(pyridin-3-yl)acrylic acid 
• 81124-48-3 methyl (E)-3-(3-pyridyl)acrylate 
• 500-22-1 3-pyridinecarboxaldehyde 
• 649766-32-5 ethyl 2-(pyridin-3-yl)cyclopropanecarboxylate 
• 59607-98-6 3-(3'-pyridinyl)-(Z)-propenoic acid ethyl ester 
• 1455271-42-7 (2E)-N-methoxy-N-methyl-3-(pyridin-3-yl)prop-2-enamide 
• 19337-97-4 trans-3-(3-pyridyl)acrylic acid 
• 100390-47-4 (E)-3-(3-pyridinyl)acrylic acid butyl ester 
• 626-55-1 3-Bromopyridine 

Relevant articles and documents

Fragment-Guided Discovery of Pyrazole Carboxylic Acid Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2 Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction

The NRF2-mediated cytoprotective response is central to cellular homoeostasis, and there is increasing interest in developing small-molecule activators of this pathway as therapeutics for diseases involving chronic oxidative stress. The protein KEAP1, which regulates NRF2, is a key point for pharmacological intervention, and we recently described the use of fragment-based drug discovery to develop a tool compound that directly disrupts the protein-protein interaction between NRF2 and KEAP1. We now present the identification of a second, chemically distinct series of KEAP1 inhibitors, which provided an alternative chemotype for lead optimization. Pharmacophoric information from our original fragment screen was used to identify new hit matter through database searching and to evolve this into a new lead with high target affinity and cell-based activity. We highlight how knowledge obtained from fragment-based approaches can be used to focus additional screening campaigns in order to de-risk projects through the rapid identification of novel chemical series.

Biphenyl urea compound as well as pharmaceutical composition, preparation method and application thereof

The invention discloses a diphenyl urea compound as well as a pharmaceutical composition, a preparation method and application thereof. The diphenyl urea compound and the pharmaceutical composition thereof have good inhibitory activity on VEGFRs and NAMPT, and have a good inhibitory effect on growth of tumor cells.

BIARYL PYRAZOLES AS NRF2 REGULATORS

The present invention relates to biaryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.